Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG-GY018: Pembrolizumab plus paclitaxel/carboplatin in advanced or recurrent endometrial cancer
jRCT2031210512Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in endometrial cancer (EC) (2 arms), sponsored by NRG Oncology. Primary endpoint: Progression-free survival. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031210512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210512.